This latest equity financing includes support from new US and international institutional investors, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority, BB Biotech AG, Julius Baer, Singapore-based EDBI, and Sequoia Capital China.
Existing investors that also participated include Fidelity Management and Research company, Pictet, Viking Global Investors, ArrowMark Partners, and Alexandria Venture Investments.
The funding will help drive the company's continued execution of its rapidly growing pipeline of 19 development candidates including 10 programmes in clinical trials.
Proceeds will also be used to further Moderna's investment in its research engine and other 2018/2019 priorities.
Privately held Moderna is developing mRNA vaccines and therapeutics as a new class of medicines for infectious diseases, cancer (immuno-oncology), rare liver diseases, cardiovascular and pulmonary diseases, through proprietary development and collaborations with strategic partners.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine